Skip to content Skip to footer
Subscribe Now
Exclusive Interview_Philip M. Brown_Dr. Anna Tallman
EXCLUSIVE

Philip Brown & Anna Tallman of Dermavant Shares Insights on the Approval of its Topical Treatment for Plaque Psoriasis

Shots:Philip spoke about plaque psoriasis, symptoms, prognosis, and treatment options available. He also discussed different ongoing patient support programs by DermavantAnna talked about the approval of Dermavant’s lead topical treatment in plaque psoriasis, its clinical studies & resultsThe interview summarizes Dermavant’s aim to develop innovative therapeutics in immuno-dermatology to address the high…
August 1, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction dataShots:The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up periodThe…
March 15, 2022

Read more